Results 11 to 20 of about 18,095,855 (237)

Spectroscopic and computational investigation of actinium coordination chemistry [PDF]

Nature Communications, 2016
Actinium-225 is a promising isotope for α-therapy but progress in developing its chemistry is hindered by its high radioactivity and short supply. Here, the authors characterize actinium coordination in HCl solutions using X-ray absorption spectroscopy ...
Maryline G. Ferrier, Enrique R. Batista, John M. Berg, Eva R. Birnbaum, Justin N. Cross, Jonathan W. Engle, Henry S. La Pierre, Stosh A. Kozimor, Juan S. Lezama Pacheco, Benjamin W. Stein, S. Chantal E. Stieber, Justin J. Wilson   +11 more
doaj   +2 more sources

Efficacy and Safety of Radioligand Therapy with Actinium-225 DOTATATE in Patients with Advanced, Metastatic or Inoperable Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Medicina
Background and Objectives: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors ...
Alessio Rizzo, Alessio Imperiale, Salvatore Annunziata, Roberto C. Delgado Bolton, Domenico Albano, Francesco Fiz, Arnoldo Piccardo, Marco Cuzzocrea, Gaetano Paone, Giorgio Treglia   +9 more
doaj   +2 more sources

Actinium-225 targeted alpha particle therapy for prostate cancer [PDF]

Theranostics
Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses.
Bidkar, Anil P, Zerefa, Luann, Yadav, Surekha, VanBrocklin, Henry F, Flavell, Robert R   +4 more
openaire   +5 more sources

Real-time trajectory imaging of alpha particles emitted from actinium-225 and its daughter radionuclides

Scientific Reports
In targeted alpha-particle therapy, actinium-225 (Ac-225) has emerged as a radionuclide of potential, driving extensive efforts to develop innovative radiopharmaceuticals.
Seiichi Yamamoto, Masao Yoshino, Kenji Shirasaki, Kohei Nakanishi, Kei Kamada, Akira Yoshikawa, Jun Kataoka   +6 more
doaj   +2 more sources

Actinium [Curatorial Project]

Artists are making the nuclear economy increasingly visible by rethinking nuclear materials and architectures, decay rates and risk perception; questioning the 20th Century belief in nuclear modernity.
Carpenter, Ele
core   +7 more sources

Production of actinium-225 from a (n,p) reaction: Feasibility and pre-design studies [PDF]

, 2021
Actinium-225 is used in nuclear medicine for the treatment of malignant tumours. It can be applied to produce Bi-213 in a reusable generator or can be used alone as an agent for radiation therapy, in particular for targeted alpha therapy.
Nisbet, Andrew, Djouider, Fathi A., Abolaban, Fouad A., Alhawsawi, Abdulsalam M., Taha, Eslam M., Banoqitah, Essam M., Eslam M. Taha, Andrew Nisbet, Fathi A. Djouider, Essam M. Banoqitah, Abdulsalam M. Alhawsawi, Fouad A. Abolaban   +11 more
core   +3 more sources

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T [PDF]

, 2022
PURPOSE: Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa).
Tamborino, Giulia, van Weerden, Wytske M.; id_orcid, Roobol, Stefan J., Konijnenberg, Mark W., de Jong, Marion, De Saint-Hubert, Marijke, Verkaik, Nicole, Nonnekens, Julie; id_orcid, Ruigrok, Eline A. M., Ruigrok, Eline A.M., de Blois, Erik, Nonnekens, Julie, van Weerden, Wytske M., Nicole Verkaik, Stefan J. Roobol, Eline A. M. Ruigrok, Giulia Tamborino, Erik de Blois, Mark W. Konijnenberg, Wytske M. van Weerden, Julie Nonnekens, Marijke De Saint-Hubert, Marion de Jong   +22 more
core   +1 more source

Clinical Application of Actinium-225 Radiopharmaceuticals in Targeted Alpha Therapy [PDF]

Research in Molecular Medicine, 2023
Among the vast variety of radionuclides available, a handful of them possess proper features for targeted alpha therapy (TAT). TAT holds the promise of exceeding the effectiveness of conventional radiotherapy methods.
Solmaz Mojarad-Jabali, Sajjad Molavipordanjani   +1 more
doaj  

Decay scheme and energy spectrum of Actinium-225.

, 2022
(A) Actinium-225 decay scheme [simplified] (B) Energy spectrum of Actinium-225 from a Siemens’ SPECT system). Dashed lines indicate gamma and X-ray emissions and their abundance, including 218 keV representing Francium-221 and 440 keV representing ...
Eleni Liapi (7044791), Yong Du (86188), Jessie R. Nedrow (1593409), Angel Cortez (11986112), Anders Josefsson (11986115), Rebecca Krimins (9250065), Mohammadreza Zarisfi (11986118)   +6 more
core   +1 more source

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +1 more source